Tumor suppressor p53 is critical for suppressing all types of human cancers, including breast cancer. The p53 gene is somatically mutated in over half of all human cancers. The majority of the p53 mutations are missense mutations, leading to the expression of the full-length p53 mutants. Several hotspot mutations, including R175H, are frequently detected in human breast cancer. P53 cancer mutants not only lose tumor suppression activity but, more problematically, also gain new oncogenic activities. Despite correlation of the expression of p53 cancer mutants and the poor prognosis of human breast cancer patients, the roles of p53 cancer mutants in promoting breast cancer remain unclear. We used the humanized p53 cancer mutant knock-in (R175H) mice and mouse mammary tumor virus (MMTV)-Wnt-1 transgenic (mWnt-1) mice to specifically address the gain of function of R175H in promoting breast cancer. Although both R175H/R175HmWnt-1(R175HmWnt-1) and p53
INTRODUCTION
Breast cancer is the most common malignancy in women worldwide. 1, 2 The tumor suppressor p53 is the most commonly altered gene in human breast cancer. 3 The importance of p53 in preventing breast cancer was also illustrated by genetically engineered mice. Conditional inactivation of p53 in mouse mammary epithelial cells (MECs) causes mammary tumors with a high rate of metastasis. 4 Deficiency of p53 promotes chromosomal instability and accelerates mammary tumorigenesis in Wnt-1 transgenic mice. 5 p53 is a transcription factor that regulates genes critical for cell cycle arrest, apoptosis and cell senescence to maintain genome stability. 6 In cancer cells, its function can be compromised by various mechanisms: mutations of Tp53, alteration of p53 regulators and alteration of p53 target genes. 7 Interestingly, the proportion of missense mutations in p53 is higher than that seen in other tumor suppressor genes, suggesting that the expression of p53 mutants may confer selective advantage over and above loss of wild-type function. 8 Accumulating data have shown that R175H mutation, a hotspot mutation found in various human cancers including breast cancer, have lost wild-type p53-dependent tumor suppression activity, and, more problematically, acquired new oncogenic properties. For example, when R175H is overexpressed in a nontransformed cell line lacking p53, it promotes tumorigenesis in immunodeficient mice, whereas the parental cell line does not. 9 Transgenic mice overexpressing R175H in epithelial cells exhibit an increased susceptibility to chemical carcinogenesis with faster tumor development when compared with mice lacking p53. 10, 11 To investigate the function of R175H in promoting cancer in a physiological context, we recently established the humanized R175H knock-in mice.
12 R175H/R175H mice develop tumors with similar kinetics as p53 À / À mice but with a more complex tumor spectrum, indicating the gain of function of R175H in tumorigenesis. In addition, R175H shares a common gain of function with other common p53 cancer mutants such as R248W in inactivating ATM function in mouse fibroblasts and thymocytes. 12, 13 Despite the convincing evidence implicating gain of function of R175H in breast neoplasia, the function of R175H in the development and progression of breast cancer remains unknown. Most R175H/R175H mice died of lymphomas, sarcomas and germ cell tumors. Therefore, to study the role of R175H in the mammary tumorigenesis, we introduced the R175H allele into the mWnt-1 transgenic mice, which express Wnt-1 transgene in the MECs under the control of the mouse mammary tumor virus (MMTV) long terminal repeat and develop mammary cancer.
14 MWnt-1 mice exhibit expanded mammary stem cell pool and spontaneously develop mammary tumors. 15 Here we found that both R175HmWnt-1 and p53
À / À mWnt-1 mice had identical survival curves. However, R175HmWnt-1 mice had an increased number of tumors in multiple mammary glands. We also found that R175H could inactivate ATM activity in mWnt-1 MECs and expand the mammary epithelial stem cell (MESC) pool.
RESULTS

R175HmWnt-1 mice developed multicentric mammary tumors with facilitated kinetics
To examine the gain of function of R175H in promoting mammary tumorigenesis, we generated R175HmWnt-1 mice, control p53 À / À mWnt-1 and mWnt-1 mice. All three strains of mice developed mammary tumors spontaneously (Figure 1a) . However, the median survival time for virgin female R175HmWnt-1 and p53
À / À mWnt-1 mice that died from breast cancer are 100.5 and 98 days, respectively, which are significantly shorter than that of mWnt-1 mice (185 days). The number of mammary tumors developed in p53
À / À mWnt-1 (on average 1.5 tumor per mouse) is slightly more than that in mWnt-1 female mice that mostly developed only one tumor (Figure 1b) . Interestingly, most R175HmWnt-1 female mice developed multiple mammary tumors that affect single or multiple mammary glands (on average 3.5 tumors per mouse) (Figure 1b) . Therefore, R175H gains new oncogenic activity to promote the mammary tumorigenesis.
In human breast cancer patients, mammary tumors with multiple foci are associated with an advanced stage, regardless of the sizes of the tumors. 16 In addition, the breast cancer patients with multicentric mammary tumors exhibit shorter survival time than patients with the unifocal or multifocal mammary cancer. 17 The histopathologic analysis of the differentiation grade of human mammary tumors remains one of the most important prognostic factors to predict the prognosis of the cancer patients. To examine whether the expression of R175H affects the differentiation state of mammary tumor, histological examination of the tumor sections showed that all the mammary tumors derived from mWnt-1 and p53
À / À mWnt-1 mice are adenocarcinomas (Figure 1c) . However, in addition to adenocarcinomas, fibroadenoma and adenoacanthoma were also found in R175HmWnt-1 À / À mWnt-1 and R175HmWnt-1 female mice are shorter than mWnt-1 (both of the P-valueo0.0001), but there is no difference between p53 À / À mWnt-1 and R175HmWnt-1 female mice (P ¼ 0.7871). P-values were calculated using log-rank test analysis. (b) The number of mammary tumors developed in mWnt-1, p53
À / À mWnt-1 and R175HmWnt-1 female mice. The number of tumors in p53 À / À Wnt-1 mice is more than that in mWnt-1 mice (P ¼ 0.0382o0.05); the number of tumors in R175HmWnt1-1 mice is more than that in mWnt-1 and p53
À / À Wnt-1 mice (Po0.0001 and P ¼ 0.0004o0.0005, respectively). P-value was obtained from unpaired, two-tailed t-test with Welch's correction. The mean number of mammary tumors in mWnt-1, p53
À / À mWnt-1 and R175HmWnt-1 female mice is 1.056, 1.600 and 3.563, respectively. *Po0.05; ***Po0.0005. À / À mWnt-1 and R175HmWnt-1 mice lost the focal gland formation and showed poor differentiation, suggesting that the mammary tumors in p53
À / À mWnt-1 and R175HmWnt-1 mice were of a more advanced stage of tumorigenesis (Figures 1c and d) .
The histological characteristics of the multiple mammary tumors developed in the same R175HmWnt-1 mouse were distinct, more fibroblast tissues was present in tumor 1(T1), while some keratinized areas in the Tumor 3 (T3), suggesting that these mammary tumors might be independent tumors ( Figure 2a) . Consistent with the findings that p53 cancer mutants are overexpressed in the human breast cancer cells, 18 the mammary cancer cells, but not their neighboring noncancerous tissues, expressed high levels of R175H, further supporting the notion that R175H promotes the mammary tumorigenesis ( Figure 2b ). Therefore, our findings of multiple tumors in the mammary glands of R175HmWnt-1 mice and the overexpression of R175H in the cancer cells support the gain of oncogenic function of R175H in promoting mammary cancer initiation.
The MESC pool is significantly expanded in R175HmWnt-1 mice The expression of oncogene Wnt-1 in MECs expands the MESC pool and induces mammary tumorigenesis, suggesting a functional link between the expansive state of the mammary stem cell and breast cancer development. 15, 19 Therefore, we analyzed the impact of R175H on the expansion of MESCs. We initially analyzed the MESCs in the wild-type, p53
À / À and R175H/R175H mammary gland using the MESCs markers Lin
þ CD29 hi as previously described. 15 Compared with MESCs in the wild-type mice, our results showed that there were no apparent differences in MESCs in the p53 À / À and R175H/R175H mice when compared with wild-type mice (Figures 3a and b) . To understand how R175H promotes mammary tumorigenesis in the presence of Wnt-1 transgene, we further analyzed the MESCs in the mammary gland of R175HmWnt-1, p53
À / À mWnt-1 and mWnt-1 mice. Although p53 deficiency led to increased MESCs in mWnt-1 mice, the expression of R175H further increased the MESC population in mWnt-1 mice when compared with p53 (Figures 3c and d) . In further support of this conclusion, using mammosphere assay widely used to evaluate MESCs with functional characteristics of stem/progenitor cells, 20 we showed increased MESCs in R175HmWnt-1 mice when compared with p53 À / À mWnt-1 mice (Figures 3e and f Table 1 and Supplement Figure S1 ). The histology of the mammary tumors developed in SCID mice transplanted with MESCs sorted from R175HmWnt-1 mice is consistent with the mammary tumor developed in R175Hmwnt-1 mice (Supplementary Figure S2 ). These results suggest that gain of function of R175H leads to the expansion of the MESC pool in the mWnt-1 mouse model that can be targeted for transformation, thus The P53 R175H mutant expands MESC X Lu et al promoting the initiation of the mammary tumorigenesis. Mammary tumors developed on both sides of the mammary empty fat reconstructed with R175HmWnt-1 mice, but never in the mammary gland of the same severe combined immunodeficient mice without the transplantation, supporting the notion that the multiple mammary tumors developed in R175HmWnt-1 mice are not due to the metastasis of a primary tumor.
Impaired ATM function in R175HmWnt-1 MECs ATM is important in suppressing mammary tumorigenesis and the expansion of normal and transformed mammary stem cells. [21] [22] [23] [24] As our previous studies have shown that the common p53 cancer mutants, including R175H, inactivate Mre11/ATM in mouse embryonic fibroblasts and thymocytes, 12 we tested whether R175H has the same gain of function in MECs. Immediately after DNA double-stranded break damage, activated ATM, which is autophosphorylated at Ser1981, was recruited to the site of DNA damage and formed IR-induced foci. When compared with that in p53 À / À mWnt-1 MECs, the IR-induced foci of phosphorylated ATM was significantly impaired in R175HmWnt1 MECs, indicating that ATM activation is impaired in R175HmWnt1 MECs after IR (Figure 4a) . Furthermore, compared with that in p53 À / À mWnt-1 MECs, the ATM-dependent phosphorylation of H2AX (g-H2AX) after IR was impaired in R175HmWnt-1 MECs (Figure 4b ). In addition, we analyzed the ATM-dependent G 2 /M checkpoint after IR, demonstrating that the G 2 /M checkpoint was significantly impaired in R175HmWnt1 MECs compared with that in À / À mWnt-1 and R175HmWnt-1 MECs. Data are mean±s.d. of three independent experiments. P-value was obtained from unpaired, two-tailed t-test with Welch's correction. *Po0.05.
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À / À mWnt-1 MECs (Figure 4c ). These results support the notion that R175H inactivates ATM in Wnt-1-expressing MECs.
Consistent with the findings that ATM suppresses the expansion of MESCs, more mammosphere formation was observed in the MECs from ATM þ / À mWnt-1 mice than those from mWnt-1 mice (Figures 4d and e) . In addition, ATM þ / À p53 þ / À mice developed mammary tumors with an increased average number of mammary tumors per mouse, indicating a role of ATM in suppressing the development of multicentric mammary tumors. Therefore, our findings support the model that R175H gains new oncogenic activities in inactivating ATM in MECs, contributing to the expansion of mammary stem cell pool and the multicentric mammary tumorigenesis. The distinct impact of R175H on MESCs in R175H and R175HmWnt-1 mice might be due to the elevated DNA damage in the mammary gland with Wnt-1 expression, because the increased DNA damage in the mammary gland as a result of Wnt-1 expression activates ATM. 25 
DISCUSSION
Although the p53 gene is frequently mutated in human breast cancer and the expression of p53 cancer mutants correlated with the poor prognosis of the breast cancer patients, the gain of oncogenic functions of p53 cancer mutants in breast cancers remains unclear. Using the common gain of function of p53 cancer mutant knock-in mice, we have identified a novel role of this common p53 cancer mutant in promoting the expansion of the MESCs that are correlated with mammary tumorigenesis. 15, 19, 26 On the basis of the findings that inactivation of ATM could expand normal and transformed MESCs, [21] [22] [23] [24] our findings that the R175H mutant inhibits ATM activity in MECs could account for the increased MESCs by inhibiting ATM activity. As ATM inactivation appears to be a common gain of function among the most frequent p53 cancer mutants, 12,13 our findings suggest that the common p53 cancer mutants could share this gain of oncogenic activity in promoting mammary tumorigenesis by inactivating ATM. Although our data point to a gain of function of R175H mutant in promoting breast cancer by inactivating ATM, we cannot rule out the possibility that one or more additional gain of functions of the R175H mutant also contribute to the breast cancer phenotype. In this context, other gain of functions of the R175H cancer mutant include the regulation of the functions of p63 and p73, 27 the TGF-beta/Smad pathway, 28 Daxx, 29 MBP1, 30 Integrin, 31 NF-Y, 32 Nuclear factor kB 33 and promyelocytic leukemia protein. 34 The contribution of these gain of functions of R175H to the increased MESCs and multiple breast cancers in R175HmWnt-1 mice remains to be investigated. Many current breast cancer therapies such as radiation therapy or treatment with topoisomerase inhibitors eliminate the cancer cells by inducing high levels of DNA DSB damage into their genome. ATM is responsible for activating cellular responses to DNA DSB damage and maintaining genomic stability. 35 Therefore, when treating p53 cancer mutant-expressing breast cancers with these DNA damage agents, the combination of impaired ATM function and the lack of effective cell death pathways might induce genetic instability and thus promote drug resistance of the breast cancer cells that survive the treatments. Our findings in this mouse model suggest that the overexpression of R175H promotes the early stage of mammary tumorigenesis partially by inactivating ATM. Therefore, destabilization of this common p53 cancer mutant and restoration of ATM function could improve the efficiency of current therapies in eliminating breast cancer cells expressing R175H.
MATERIALS AND METHODS
Isolation and culture of primary MECs from mouse MECs were isolated as described earlier. 15 Breast glands were dissected from 8-week-old female mice, and minced with a razor blade. The tissue was placed in culture medium (DMEM/F12 with 1 mM glutamine, 5 mg/ml insulin, 500 ng/ml hydrocortisone, 10 ng/ml epidermal growth factor and 20 ng/ml cholera toxin) supplemented with 5% fetal bovine serum (Hyclone, South Logan, UT, USA) and containing 300 U/ml collagenase IV (Invitrogen, Grand Island, NY, USA) and 100 U/ml hyaluronidase (Sigma, St Louis, MO, USA), and digested for 1 h at 37 1C. The resultant organoid suspension was sequentially digested in 0.25% trypsin-EGTA for 2 min, 5 mg/ml dispase (Stemcell Technologies, Vancouver, Canada) and 0.1 mg/ml DNase (Stemcell Technologies) for 5 min and 0.64% NH 4 Cl for 3 min before filtration through a 40-mm cell strainer. The filtrated cells ware cultured or labeled. The cell culture medium was used as described earlier. 36 Cells were cultured in complete growth media containing 5 mg/ml insulin, 1 mg/ml hydrocortisone (Sigma), 3 ng/ml epidermal growth factor, 10% fetal bovine serum and 50 U/ml penicillin/streptomycin in DMEM/F12 (Invitrogen). All cultures were maintained at 37 1C in a 5% CO 2 atmosphere.
Histology analysis
Mammary gland and mammary cancer samples were fixed in 10% buffered formalin, embedded in paraffin and sliced. All sections were stained with hematoxylin and eosin for histological assessment as previously described; 12 the PAb1081 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for immunochemistry.
Flow cytometric analysis
Cells were stained at a concentration of 1 Â 10 6 cells per 100 ml of fluorescence-activated cell-sorting buffer (1 Â phosphate-buffered saline with 2% fetal bovine serum and 0.09% sodium azide). Cells were first labeled with biotin-conjugated anti-mouse TeR-119, CD45 and CD31 (eBioscicence, San Diego, CA, USA) at appropriate dilutions at 4 1C for 15 min, and then washed with fluorescence-activated cell-sorting buffer three times and stained with APC-strepavidin (eBioscience), PE-anti-CD24 (Biolegend, San Diego, CA, USA) and FITC-anti-CD29 (Biolegend) at appropriate dilutions at 4 1C for 15 min. The stained samples were then analyzed using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA, USA). Cell sorting was carried out on a BD FACSAria II cell sorter (BD Biosciences).
Mammosphere culture
Mammosphere culture was performed as described. 20 The isolated MECs were cultured in MEC culture medium for 1 day. Single cells were plated in ultralow attachment plates (Corning, Corning, NY, USA) at a density of 25 000 viable cells/ml in primary culture. Cells were grown in a serum-free mammary epithelial growth medium (Lonza, Walkersville, MD, USA), supplemented with B27 (Invitrogen), 20 ng/ml epidermal growth factor (Sigma), 20 ng/ml bFGF (Invitrogen) and 4 mg/ml heparin (Sigma). Half of the medium was changed every 3 days. The mammospheres were cultured for 20 days, and the ones with a diameter 450 mm were counted.
Cell cycle analysis
To analyze the G2-M checkpoint, asynchronously growing MECs were irradiated (2 and 5 Gy) and harvested 1 h after treatment. Cells in mitosis were identified by staining with propidium iodide for DNA content and FITC-conjugated antibody recognizing Histone 3 phosphorylated at Ser 10 (Millipore, Temecula, CA, USA).
Western blotting analysis
Protein extract from 4 Â 10 5 MECs was resolved on 12-15% SDS polyacrylamide gel and transferred to nitrocellulose membrane, which was probed with anti-g-H2AX and anti-H2A antibodies (Cell Signaling Technology, Danvers, MA, USA). The membrane was subsequently probed with a horseradish peroxidase-conjugated secondary antibody and developed with Super signal West Dura (Thermo, Rockford, IL, USA).
Immunoflorescence microscopy Primary MECs grown on Lab-TekTM Chamber Slide (Thermo) were exposed to 2 Gy of IR, and 1 h later fixed with methanol. The fixed cells were blocked with 3% bovine serum albumin in phosphate-buffered saline for 30 min at room temperature, and incubated with mouse monoclonal antibody recognizing ATM phosphorylated at Ser1981 (1:600 dilution; Rockland Inc., Gilbertsville, PA, USA) in 1% bovine serum albumin in phosphate-buffered saline overnight at 4 1C. After washing, the cells were incubated with secondary antibodies for 1 h at room temperature. After mounting on glass slides with VECTASHIELD mounting media with 4, 6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA), images were acquired using an Olympus confocal microscope (Olympus America Inc, Center Valley, PA, USA).
